Beijing Institute of Otolaryngology Report issue

Academic/Hospital Phase 3
Founded: Beijing China (1953)

Organization Overview

First Clinical Trial
2009
NCT01291381
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Beijing Institiute of Otolaryngology | Beijing Institute of Otolaryngology

Active Ingredients

Drugs in Phase 3 Trials (1)

budesonide (rhinocort) (3 trials)

Drugs in Other Trials (2)

house dust mite allergen (1 trial)

levocabastine (livostin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nasal Polyps (Phase 3)

Polyps (Phase 3)

Rhinitis (Phase 1)

Rhinitis, Allergic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3